Abstract
Background: No survival benefit was shown in the randomized Asian REGATTA trial for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single non-curable factor; thereby discouraging palliative gastrectomy surgery for this group of patients. The German prospective phase II AIO-FLOT3 trial indicated a favourable survival for patients with limited metastastic disease having surgery after neoadjuvant chemotherapy, and this is further being evaluated in the ongoing randomized RENAISSANCE trial. The aim of this study was to describe treatment strategy patterns for patients with metastatic gastric cancer in daily practice in five countries in Europe. Also, relative survival according to country was determined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
